Updated Saturday, July 21, 2018
 Journal Tools
RSS Feed
Sample Copy
Submit a Manuscript
Contact Us
Subscription
Advertising
Thanking Peer Reviewers
 Language Polishing
Journal of Integrative Medicine: Volume 11, 2013   Issue 6,  Pages: 428-434

DOI: 10.3736/jintegrmed2013059
Study Protocol
Chinese herbal medicine Xinfeng Capsule in treatment of rheumatoid arthritis: study protocol of a multicenter randomized controlled trial
1. Jian Liu (Department of Rheumatology, the First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China E-mail: liujianahzy@126.com)
2. Chuan-bing Huang (Department of Rheumatology, the First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China )
3. Yuan Wang (Department of Rheumatology, the First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China )
4. Gui-qin Xu (Department of Rheumatology, the First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China )
5. Yuan-yuan Cheng (Department of Rheumatology, the First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China )
6. Yun-xia Feng (Department of Rheumatology, the First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China )
7. Lei Liu (Department of Rheumatology, the First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China )
8. Ya-jun Qi (Department of Rheumatology, the First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China )

BACKGROUND: Rheumatoid arthritis (RA), as a common systemic inflammatory autoimmune disease, affects approximately 1 in 100 individuals. Effective treatment for RA is not yet available because current research does not have a clear understanding of the etiology and pathogenesis of RA. Xinfeng Capsule, a patent Chinese herbal medicine, has been used in the treatment of RA in recent years. Despite its reported clinical efficacy, there are no large-sample, multicenter, randomized trials that support the use of Xinfeng Capsule for RA. Therefore, we designed a randomized, double-blind, multicenter, placebo-controlled trial to assess the efficacy and safety of Xinfeng Capsule in the treatment of RA.

METHODS AND DESIGN: This is a 12-week, randomized, placebo-controlled, double-blind, multicenter trial on the treatment of RA. The participants will be randomly assigned to the experimental group and the control group at a ratio of 1:1. Participants in the experimental group will receive Xinfeng Capsule and a pharmaceutical placebo (imitation leflunomide). The control group will receive leflunomide and an herbal placebo (imitation Xinfeng Capsule). The American College of Rheumatology (ACR) Criteria for RA will be used to measure the efficacy of the Xinfeng Capsule. The primary outcome measure will be the percentage of study participants who achieve an ACR 20% response rate (ACR20), which will be measured every 4 weeks after randomization. Secondary outcomes will include the ACR50 and ACR70 responses, the side effects of the medications, the Disease Activity Score 28, RA biomarkers, quality of life, and X-rays of the hands and wrists. The first four of the secondary outcomes will be measured every 4 weeks and the others will be measured at baseline and after 12 weeks of treatment.

DISCUSSION: The result of this trial will help to evaluate whether Xinfeng Capsule is effective and safe in the treatment of RA.

TRIAL REGISTRATION: This trial has been registered in ClinicalTrials.gov. The identifier is NCT01774877.

Welcome to JIM! You are the number 27174 reader of this article!
Download Article:
[Full Text]      [PDF]      [Previous]      [This Issue]
Please cite this article as:
Liu J, Huang CB, Wang Y, Xu GQ, Cheng YY, Feng YX, Liu L, Qi YJ. Chinese herbal medicine Xinfeng Capsule in treatment of rheumatoid arthritis: study protocol of a multicenter randomized controlled trial. J Integr Med. 2013; 11(6): 428-434.
References:
1Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis[J].Am J Manag Care, 2012, 18(13 Suppl): s295-s302.  
2Chopra A, Abdel-Nasser A. Epidemiology of rheumatic musculoskeletal disorders in the developing world[J].Best Pract Res Clin Rheumatol, 2008, 22(4): 583-604.  
3Evans S, Cousins L, Tsao JC, Subramanian S, Sternlieb B, Zeltzer LK. A randomized controlled trial examining Iyengar yoga for young adults with rheumatoid arthritis: a study protocol[J].Trials, 2011, 12: 19.  
4McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis[J].N Engl J Med, 2011, 365(23): 2205-2219.  
5Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O’Dell J, Winthrop KL, Beukelman T, Bridges SL, Jr. , Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis[J].Arthritis Care Res (Hoboken), 2012, 64(5): 625-639.  
6Sehgal VN, Verma P. Leflunomide: dermatologic perspective[J].J Dermatolog Treat, 2013, 24(2): 89-95.  
7Yoo HG, Yu HM, Jun JB, Jeon HS, Yoo WH. Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide[J].Mod Rheumatol, 2013, 23(4): 709-715.  
8Zhang C, Jiang M, Lu AP. Evidence-based Chinese medicine for rheumatoid arthritis[J].J Tradit Chin Med, 2011, 31(2): 152-157.  
9Liu J, Liu RL. The potential role of Chinese medicine in ameliorating extra-articular manifestations of rheumatoid arthritis[J].Chin J Integr Med, 2011, 17(10): 735-737.  
10Cao YX, Liu J, Zhu Y. Effect of xinfeng capsule on the cardiac function in patients with rheumatoid arthritis[J].Chin J Integr Med, 2011, 17(10): 738-743.  
11Feng Y, Liu J, Cheng Y, Wan L. Protective mechanism of XinFeng capsule on Sj?gren syndrome rat pulmonary function based on the TGF-beta1-ERK1 signal pathway[J].Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2013, 29(2): 118-122.  
12Wan L, Liu J, Huang C, Wang Y, Shen X, Zhang W, Wang G, Fan H, Ge Y, Chen R, Cao Y, Zong R, Lei L. Effects of Xinfeng Capsule on pulmonary function based on treg-mediated notch pathway in a rat model of adjuvant arthritis[J].J Tradit Chin Med, 2012, 32(3): 430-436.  
13Rui-Kai Z, Jian L. Effects of Xinfeng capsules on expression of platelet granule membrane protein 140 and platelet cluster of differentiation 40 ligand in peripheral blood of adjuvant arthritis rats[J].Int J Rheumatol, 2012, 2012: 139696.  
14Liu L, Zheng ZJ, Fang ZH. Experimental study on effect of xinfeng capsule in treating rats’ adjuvant arthritis on ultrastructure of synoviocyte and splenic lymphocyte[J].Zhongguo Zhong Xi Yi Jie He Za Zhi, 2001, 21(12): 917-919.  
15Wan L, Liu J, Huang CB, Wang Y, Shen X, Zhang WD, Wang GZ, Fan HX, Ge Y, Chen RL, Cao YX, Zong RK. Effect of Xinfeng Capsule on lung function in rats with adjuvant-induced arthritis and its mechanism[J].Zhejiang Da Xue Xue Bao Yi Xue Ban, 2013, 42(4): 418-425.  
16Liu J, Yu XF, Zong RK. Effects of Xinfeng Capsule on behaviors and myocardial ultrastructure in adjuvant arthritis rats[J]. J Chin Integr Med, 2008, 6(6): 606-610.  
17Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J].Arthritis Rheum, 2010, 62(9): 2569-2581.  
18American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update[J].Arthritis Rheum, 2002, 46(2): 328-346.  
19Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation[J].J Rheumatol, 2003, 30(1): 167-178.  
20Zhang M. Handbook of rating scales in psychiatry[M]. Changsha: Changsha Science and Technology Press, 2003. 35, 39.  
21Ortiz Z, Shea B, Garcia Dieguez M, Boers M, Tugwell P, Boonen A, Wells G. The responsiveness of generic quality of life instruments in rheumatic diseases. A systematic review of randomized controlled trials[J].J Rheumatol, 1999, 26(1): 210-216.  
22Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, Xu J, Li X, Liu J, Sun L, He P, Ma J, Xu S, Ding C. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial[J].Chin Med J (Engl), 2003, 116(8): 1228-1234.  
23Wang J. Clinical epidemiology — design, measurement and evaluation[M]. Shanghai: Shanghai Science and Technology Press, 2009. 165.  
24Xiong NN, Zou JD, Jiang M. A design for a randomized protocol of multicenter clinical trial[J].Zhong Yao Xin Yao Yu Lin Chuang Yao Li, 2002, 13(5): 321-323, 341.  
25Li Y, Zheng H, Zeng F, Zhou SY, Zhong F, Zheng HB, Chen M, Jing XH, Cai YY, Jia BH, Zhu B, Liu ZS. Use acupuncture to treat functional constipation: study protocol for a randomized controlled trial[J].Trials, 2012, 13: 104.  
26Yu XQ, Li JS, Li SY, Xie Y, Wang MH, Zhang HL, Wang HF, Wang ZW. Functional and psychosocial effects of pulmonary Daoyin on patients with COPD in China: study protocol of a multicenter randomized controlled trial[J]. J Integr Med, 2013, 11(2): 140-146.  
27Xu WD, Zhang M, Feng CC, Yang XK, Pan HF, Ye DQ. IL-32 with potential insights into rheumatoid arthritis[J].Clin Immunol, 2013, 147(2): 89-94.  
28Hu PF, Chen Y, Cai PF, Jiang LF, Wu LD. Sphingosine-1-phosphate: a potential therapeutic target for rheumatoid arthritis[J].Mol Biol Rep, 2011, 38(6): 4225-4230.  
29Schiff M, Peura D. HZT-501 (DUEXIS?; ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis[J].Expert Rev Gastroenterol Hepatol, 2012, 6(1): 25-35.  
30Zhang EQ. Bi syndrome (Arthralgia Syndrome)[J].J Tradit Chin Med, 2010, 30(2): 145-152.  
31Wang ZZ, Fang YF, Wang Y, Mu FX, Chen J, Zou QH, Zhong B, Li JY, Bo GP, Zhang RH. Logistic regression analysis of damp-heat and cold-damp impeding syndrome of rheumatoid arthritis: a perspective in Chinese medicine[J].Chin J Integr Med, 2012, 18(8): 575-581.  
32Jiang M, Zha Q, He Y, Lu A. Risk factors of gastrointestinal and hepatic adverse drug reactions in the treatment of rheumatoid arthritis with biomedical combination therapy and Chinese medicine[J].J Ethnopharmacol, 2012, 141(2): 615-621.  
33Zhang J, Ma YZ, Shen XM. Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson’s disease: study protocol of a multicenter, open-label, randomized active-controlled trial[J]. J Integr Med, 2013, 11(4): 285-290.  
 Home | Current Issue | Past Issues | SearchRSS
Copyright © 2013-2018 by JIM Editorial Office. All rights reserved. ISSN 2095-4964; CN 31-2083/R. 沪ICP备110264号